Government Approval of MDMA for Treating PTSD Likely
For the millions of Americans suffering from Posttraumatic Stress Disorder (PTSD), there may finally be a solution. A late-stage clinical trial of the psychedelic drug MDMA has shown great promise in treating the condition, making FDA approval likely in the next few years.
MDMA, an illegal drug commonly known as “ecstasy” or “molly” started out as a synthetic compound created in 1912. After a period of use in the treatment of mental health conditions, it escaped in the 1980s from the clinic to the dance floor and was criminalized by the FDA. But a few proponents continue to push for research, including Dr. Rick Doblin who founded the Multidisciplinary Association for Psychedelic Studies, or MAPS.
Decades later their efforts finally led to a green light from the FDA for clinical study. Since then, there have been three rigorous clinical trials, which have all shown enormous promise of the drug in combination with psychotherapy to treat PTSD.
Watch more:
About the Author
New Studies Find Psychedelics Highly Effective for Alcoholism
New studies show unprecedented success in the treatment of alcoholism with psychedelic therapy.
The psychedelic revolution in mental health has produced overwhelming scientific evidence demonstrating the great efficacy of psychedelics in the treatment of various mental health disorders. Now, several new studies involving the drugs ketamine and MDMA are showing significant promise in the treatment of alcoholism.
Dr. Ben Sessa is a psychiatrist and chief medical officer at Awakn Life Sciences, an English biotech company that is at the forefront of the research, development, and delivery of psychedelic medicines.
The company is especially focused on the treatment of Alcohol Use Disorder or AUD, given how prevalent and challenging it is to treat.
“Alcoholism is a huge public health problem. It’s also a psychiatric condition that’s very poorly treated with very poor outcomes with traditional methods,” Sessa said. “Relapse to drinking after getting dry is around 80 to 90 percent at 12 months. That’s an embarrassingly poor statistic. Psychedelics offer a completely new approach; they offer the patient to explore the root causes of addiction, which so often is trauma. Psychedelic-assisted psychotherapy is an intensive upfront piece of work that gets the patient better, so they don’t have to keep coming back. It is a completely different paradigm shift to the way we currently manage patients in maintenance therapies.”Â
A recent study conducted by researchers at the University of Exeter and Awakn Life Sciences is the world’s first to examine the use of ketamine to treat AUD in a randomized controlled trial.
“Ketamine is a very well-established human medicine. It is indeed the only psychedelic that’s licensed as a medicine, as an anesthetic medicine, and has been used since the 60s as such. It’s an incredibly safe medicine. When it’s used at a much lower dose, it produces an altered state of consciousness. What we do in psychedelic-assisted psychotherapy with ketamine, is we use this altered state of consciousness to affect a more effective and deeper form of psychotherapy. So, we’re using ketamine as an adjunct to psychotherapy to treat addictions,” he said. Â
